A global Unified Dosimetry Index (gUDI) to evaluate simultaneous integrated boost radiotherapy plans in prostate cancer

Publication date: Available online 23 June 2018
Source:Radiotherapy and Oncology
Author(s): Maddalena Mambretti, Chiara Romanò, Giulia Marvaso, Stefania Comi, Raffaella Cambria, Delia Ciardo, Francesca Emiro, Cristiana Fodor, Dario Zerini, Giulia Riva, Giuseppe Petralia, Ottavio De Cobelli, R. Orecchia, Federica Cattani, Barbara Alicja Jereczek-Fossa
PurposeFormulation of a global Unified Dosimetry Index (gUDI) for the evaluation of prostate simultaneous integrated boost Volumetric Modulated Arc Therapy (VMAT by RapidArc) radiotherapy plans.Methods and materialsDose coverage, conformity, homogeneity and dose gradient index could be included in the Unified Dosimetry Index (UDI). We developed a global UDI to evaluate treatment plans containing volumes irradiated with different dose prescriptions: Intensity Modulated Radiation Therapy with simultaneous integrated boost (IMRT-SIB) with 2 dose levels (36.25 Gy/5 fz for the whole prostate gland and 37.5 Gy/5 fz for Dominant Intraprostatic Lesion (DIL)).To validate gUDI scoring system, 65 prostate cancer patients were evaluated. Mean (µ) and standard deviations (σ) were calculated for all dosimetry indices and gUDI. Furthermore, gUDI µ and σ were analyzed to compare and classify treatment plans: plans can be ranked as "excellent", "good", "average" or "poor".ResultsProstate Dose Gradient, Prostate Conformity and DIL Conformity indices had highlighted a major deviation from ideal scores. gUDI index classification showed most of the plans scored as "average" and "good".ConclusiongUDI score can be a useful tool to quantify treatment plans quality also when volumes with different dose-prescription are treated.



https://ift.tt/2MVn1BR